Printer Friendly

BioTime To Present Data From Dry AMD Study At ARVO.

ALAMEDA, Calif, April 16, 2019 -- Bio-Time, Inc. (NYSE American: BTX) said it will present updated results at an upcoming ophthalmology meeting from a Phase l/2a clinical study of its lead product candidate, OpRegen, a retinal pigment epithelium (RPE) cell transplant therapy in development for the treatment of dry age-related macular degeneration (AMD) with geographic atrophy.

The data will be presented at the Association for Research in Vision and Ophthalmology annual meeting held April 28 through May 2 in Vancouver, B.C., Canada.

"Phase l/2a Clinical Trial of Human Embryonic Stem Cell (hESC)-Derived Retinal Pigmented Epithelium (RPE, OpRegen) Transplantation in Advanced Dry Form Age-Related Macular Degeneration (AMD): Interim Results" will be presented on May 2 by Eyal Banin of Hadassah-Hebrew University Medical Center.

The abstract will provide updated data from patient cohorts 1 through 3 of the study and new data from cohort 4 in better vision patients.

In addition, BioTime will present preclinical results from its Vision Restoration Program, the company's proprietary research program focused on developing technology that allows the generation of three-dimensional human retinal tissue derived from human pluripotent cells.

BioTime's three-dimensional retinal tissue technology would address a wide range of severe retinal degenerative conditions (e.g., retinitis pigmentosa and advanced forms of AMD) through a retinal tissue restoration strategy.

In 2017, the Small Business Innovation Research program of the National Institutes of Health awarded BioTime a grant of up to $1.56 million to further develop this innovative, next generation vision restoration

program.

"Transplantation of human embryonic stem cell derived retinal tissue in the subretinal space of immunodeficient rats with retinal degeneration (RD)" will be presented on April 30 by Igor Nasonkin of BioTime.

"Evaluation of selected Human Embryonic Stem Cell Lines for differentiation to three-dimensional retinal tissue (organoids) for cell therapies of retinal degenerative conditions" will be presented on April 30 by Ratnesh Singh of BioTime.

OpRegen is a retinal pigment epithelium transplant therapy in Phase l/2a development for the treatment of dry AMD, the leading cause of adult blindness in the developed world.

OpRegen is a suspension of RPE cells delivered sub-retinally as an intraocular injection.

Contact: http://www.biotimeinc.com

COPYRIGHT 2019 DataTrends Publications, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Top of the News...
Publication:Stem Cell Business News
Article Type:Clinical report
Date:Apr 29, 2019
Words:360
Previous Article:Updated Phase 2a Results For First Stem Cell Trial In ACLF.
Next Article:Magenta To Present Preclinical Data From Stem Cell Gene Therapy Expansion Program.
Topics:

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters